TFX 📈 Teleflex - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8793691069
TFX: Catheters, Pumps, Surgical Instruments, Anesthesia Devices, Urology Products
Teleflex Incorporated is a global leader in the design, development, manufacture, and supply of single-use medical devices, catering to a wide range of diagnostic and therapeutic procedures in critical care and surgical applications. The company's product portfolio is diverse, with a focus on vascular access products, including Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems. These products enable the administration of intravenous therapies, measurement of blood pressure, and withdrawal of blood samples through a single puncture site, streamlining clinical workflows and improving patient outcomes.
The company's interventional products are another key area of focus, comprising coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platforms. These products are used by interventional cardiologists, radiologists, and vascular surgeons to treat a range of cardiovascular conditions. Additionally, Teleflex offers a range of anesthesia products, including airway and pain management solutions, which support hospital, emergency medicine, and military channels. Its surgical products, such as metal and polymer ligation clips and fascial closure surgical systems, are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments, facilitating minimally invasive surgeries and reducing recovery times.
Teleflex also has a significant presence in the fields of interventional urology, respiratory care, and urology. Its UroLift System, for example, is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia. The company's respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products, are used in various care settings to support patients with respiratory conditions. Furthermore, its urology products, such as catheters, urine collectors, and catheterization accessories, are designed to meet the needs of healthcare providers and patients in operative endourology and other urological applications.
With a strong commitment to innovation and customer satisfaction, Teleflex serves a broad range of markets, including hospitals and healthcare providers, medical device manufacturers, and home care markets. Founded in 1943 and headquartered in Wayne, Pennsylvania, the company has established itself as a trusted partner in the healthcare industry, with a global presence and a reputation for delivering high-quality medical devices and solutions. Its common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol TFX, and it is classified under the GICS Sub Industry: Health Care Equipment, with the ISIN US8793691069.
Additional Sources for TFX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TFX Stock Overview
Market Cap in USD | 8,232m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1988-02-18 |
TFX Stock Ratings
Growth 5y | -71.7% |
Fundamental | 22.4% |
Dividend | 41.0% |
Rel. Strength Industry | -1417 |
Analysts | 3.36/5 |
Fair Price Momentum | 145.13 USD |
Fair Price DCF | 250.70 USD |
TFX Dividends
Dividend Yield 12m | 0.76% |
Yield on Cost 5y | 0.37% |
Annual Growth 5y | 4.56% |
Payout Consistency | 95.8% |
TFX Growth Ratios
Growth Correlation 3m | -95.4% |
Growth Correlation 12m | -40.1% |
Growth Correlation 5y | -80.8% |
CAGR 5y | -13.31% |
CAGR/Mean DD 5y | -0.43 |
Sharpe Ratio 12m | -1.17 |
Alpha | -55.70 |
Beta | 1.05 |
Volatility | 32.25% |
Current Volume | 1355.9k |
Average Volume 20d | 499.6k |
As of December 21, 2024, the stock is trading at USD 178.16 with a total of 1,355,914 shares traded.
Over the past week, the price has changed by -4.65%, over one month by -9.47%, over three months by -28.73% and over the past year by -30.70%.
Neither. Based on ValueRay Fundamental Analyses, Teleflex is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 22.43 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TFX as of December 2024 is 145.13. This means that TFX is currently overvalued and has a potential downside of -18.54%.
Teleflex has received a consensus analysts rating of 3.36. Therefor, it is recommend to hold TFX.
- Strong Buy: 0
- Buy: 5
- Hold: 9
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TFX Teleflex will be worth about 159.8 in December 2025. The stock is currently trading at 178.16. This means that the stock has a potential downside of -10.29%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 242.6 | 36.2% |
Analysts Target Price | 252.3 | 41.6% |
ValueRay Target Price | 159.8 | -10.3% |